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Objectives. To investigate the usage patterns and adherence rates with the quadrivalent HPV (qHPV)
vaccine at Naval Medical Center San Diego.
Methods. This retrospective, cross-sectional study was conducted by using AHLTA (Electronic Health
Record of DoD) to identify all qHPV recipients between 2006 and 2009. Charts were reviewed to extract
demographic variables and immunization schedules for association analysis. Subjects were assigned
intention-to-treat (ITT) if they initiated the series and reached the 1-year anniversary after dose-1 or in-
progress (IP) if the series was incomplete and within 1-year. ITT subjects were designated non-adherent or
adherent based on 1–2 or 3 doses received.
Results. 6792 females and 46maleswith respectivemean ages (years) of 19 (95% CI: 10–29) and 27 (95% CI: 9–
46) initiated the qHPV series. The evaluable ITT population consisted of 5088 females and 31males. The adherence
rate for femaleswas 32% (1656/5088) versus 3% (1/31) formales. For females, adherence declined from45%, 24%, to
14%with respect to increasing age: 8–17, 18–26, 27–50 years. Adherence declined accordingly by beneficiary status:
dependent daughters (43%), spouses (21%) and active duty (16%); and by clinic of vaccine initiation: Pediatrics/
Adolescent (45%), Primary Care (38%), Immunization (21%), and OB/GYN (9%). Males were predominantly active
duty 84%, vaccinated through immunization clinics 84%, and poorly adherent 3%.
Conclusions.Optimal HPV immunization efficacy is derived from vaccine adherence and HPV naivety. This study
of qHPV adherence has provided insight into real-world suboptimal use post-marketing. Usage patterns and
adherence rates were significantly associated with demographic characteristics.
Published by Elsevier Inc.
Introduction
On June 8, 2006, the United States Food and Drug Administration
(FDA) announced the approval of Gardasil™HPVvaccine for licensure [1].
It was the world's first vaccine developed to prevent human papilloma-
virus (HPV) infectionsandassociateddiseases. Thevaccinewasbrought to
market after years of collective research by multiple institutions around
the world to include the University of Rochester, Georgetown University,
Queensland University in Australia, the U.S. National Cancer Institute, and
Merck & Co. [2]. Since licensure, Gardasil™ has been approved in 123
countries with over 50 million doses distributed worldwide [3,4]. In the
United States alone, 33 million doses have been distributed but the actual
administered doses are unknown [5].
Initially approved for females between the ages of 9 and 26 in the
United States, the indications for Gardasil™ have expanded and
evolved over the last 5 years [6]. On October 16, 2009, the FDA
extended the vaccine indication to include boys and men ages 9–26
for the prevention of genital warts caused by HPV types 6 and 11 [7,8].
Then on December 22, 2010, the FDA again broadened the indication
to include prevention of anal intraepithelial lesions and cancer [9].
Most recently, the safety and immunogenicity profile of the vaccine in
women ages 27–45 was added to the product information [10,11].
Prior to FDA approval, select physicians administered the vaccine off-
label to men engaged in high-risk sexual behavior.
The quadrivalent vaccine (qHPV) manufactured by Merck & Co.
(Whitehouse Station, NJ) is based on virus-like particles (VLPs)
assembled from recombinant HPV capsid proteins that are antigenic
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for HPV-6/11/16/18 [12]. The approval of the vaccine was based on
multiple studies that documented its efficacy [7–14]. Specifically, the
Per-Protocol-Efficacy against cervical intraepithelial neoplasia (CIN2+)
and condylomata and anal lesions in males were 98%, 89% and 78%,
respectively. However, the intention-to-treat efficacy (recipient of at
least 1 dose and regardless of serology and genital HPV DNA status to
qHPV types) dropped significantly for the respective lesions: 44%, 67%,
and 50% [7–14]. These studies and others indicate that the greatest
efficacy is derived from vaccine adherence and maintenance of HPV
naivety throughout the vaccination period.
Currently, the U.S. national qHPV usage patterns and adherence
rates since licensure are not explicit. The only glimpse is offered by the
CDC's National Immunization Survey-Teen (NIS-Teen) initiated in
2006 to estimate vaccination coverage from a national sample of
adolescents aged 13–17 years [15,16]. Among adolescent girls
surveyed in 2007 (n=1440) and 2008 (n=8607), the percentage
of those who initiated the vaccine series increased from 25.1% to
37.2%. However, the 3-dose completion rate (only available for the
2008 recipients) was 48.1% [16]. This preliminary national statistic
suggests “real-world” qHPV adherence rates may be underwhelming
with compromised efficacy.
From clinical trials, qHPV has demonstrated superb efficacy under
controlled, per-protocol conditions. However, vaccine adherence in the
general female population as reported by a handful of academic medical
centers suggests considerable incompletion rates [17–19]. This cross-
sectional study was undertaken to determine the post-marketing qHPV
adherence rates in the unstudied U.S. military population. We aimed to
investigate all qHPV recipients, regardless of age, gender, or status to avoid
exclusion bias and to gain insight to qHPV utilization among medical
specialties. Secondarily, vaccine usage characteristics and patterns were
gleaned to examine its association with adherence.
Materials and methods
Approval to conduct this study was obtained from the Institutional
Review Board of NavalMedical Center SanDiego (NMCSD), California. A
retrospective, cross-sectional study was conducted by using AHLTA
(Electronic Medical Record of the Department of Defense), to search for
patients who received qHPV vaccination at NMCSD and its affiliated
clinics from July 2006 to April 2009. The following Current Procedural
Terminology (CPT) and Diagnosis codes: 90649 (HPV vaccine) and
V04.89 (need for prophylactic vaccination and inoculation against;
other viral diseases) were used to generate the listing of patients. The
timeperiod chosenmarked the initiationof qHPVvaccination atNMCSD
to data collection. After patient identification and verification of
vaccination, an electronic chart review was performed to extract
variables of interest: demographics (age, gender, and military/benefi-
ciary status), clinic of origination by specialty, and vaccination
schedules. Specifically, the qHPV vaccination data for each subject was
recorded as CPT code 90649with accompanying date, dosage and site of
administration. If the date of the 1st dose was in question, a detailed
review of the clinician's progress note in AHLTA and/or calculation of
dosing interval (2 versus 4 months between the 1st and 2nd or 2nd and
3rd doses) assisted in assignment of proper dose order. Patients were
not contacted for additional clinical information.
We analyzed the receipt of the qHPV doses according to the dose
and schedule recommended by the Advisory Committee on Immuni-
zation Practices (ACIP) [12]. The timeframe permitted for completion
of the 3-dose series is 1 year as defined in the FUTURE II trial [13].
Timeliness of immunization was defined as the recommended
schedule at month 2±1 month and month 6±2 months. This was
based on the anti-HPV immunogenicity profile of 18–26 year-old
women derived from Merck sponsored clinical trials which showed
timing flexibility (detailed above) did not adversely impact the
immune responses to Gardasil™ [20]. Of note, this is in contradis-
tinction to childhood immunizations which generally defines
“delayed” vaccination as inoculation 4 weeks past the recommended
age range [21,22]. For subject allocation, we applied the intention-to-
treat principle which is an analysis based on initial treatment intent,
not on eventual treatment administered. Hence, the intention-to-
treat (ITT) subjects were defined as those who initiated the vaccine
series and reached the 1-year anniversary after dose #1 (regardless of
receipt of doses 2 or 3). Patients who had not completed the 3-dose
series, but still within the 1-year timeframe for completion were
defined as in-progress (IP) subjects. The ITT subjects were further
categorized as “non-adherent” or “adherent” to the 3-dose regimen
based on 1–2 or 3 doses received, respectively.
Naval Medical Center San Diego is composed of a large multi-
specialty medical center with 10 branch clinics. A total of 49 separate
“clinic type” codes were identified by the visits of the vaccinated
subjects. For simplicity of systemization, these clinics were grouped
into 4 broad medical specialties, i.e. Pediatrics/Adolescent, Primary
Care, Immunization, and Obstetrics/Gynecology which served as each
subject's clinic of qHPV initiation.
Data were summarized using means (95%), medians (IQR), and
proportions. Odds and odds ratios were calculated as a measure of
association between predictor and outcome variables. The odds-of-
vaccination was defined as the probability that the event will occur to
the probability that the event will not occur (Odds=P/1–P). In this
study, the group with the highest odds (probability of receiving the
dose than not) was used as the reference group within each
demographic category (age group, beneficiary status, and clinic
specialty). Categorical variables were compared using the χ2 test or
Fisher's exact test as appropriate. P valuesb0.05 were regarded as
significant. All statistical analyses were performed with statistical
software STATA 11/IC (StataCorp LP, College Station, TX).
Results
A total of 6838 patients initiated the qHPV vaccine during the
study period. The study population was predominantly female
(n=6792) with a mean age of 19 years (95% CI: 10 to 29)
(Supplementary Fig. S1). The male population constituted only 46
patients with amean age of 27 years (95% CI: 9 to 46) (Supplementary
Fig. S1). After assignment of the total population to either the ITT or IP
groups, further analysis was conducted after excluding IP patients
(female: n=1704; male: n=15). The remaining 5088 female ITT
subjects emerged as the focus of our analysis and results in contrast to
the data derived from the small subset of male ITT subjects (n=31).
For the female population, the details of the demographic data and
vaccine adherence rates bydose number are presented in Table 1. Of the
cohort who initiated the vaccine series, 5088/6792 subjects (75%)
reached the 1-year anniversary and was deemed evaluable. Vaccine
adherence declined precipitously for the 2nd dose (2879/5088 subjects
(56.6%)) to the 3rd dose (1656/5088 subjects (32.5%)), (χ2, Pb0.001).
The adherence rate (3-doses) also declined with increasing age (Fig. 1).
After segregating the ITT subjects into 3 age groups (8–17, 18–26, 27–
50 years), the respective adherence rates for the 3rd dose were
(959/2146 (45%), 676/2794 (24%), 20/148 (14%), (χ2, Pb0.001)).
Beneficiary status was also found to be associated with adherence.
The 3-dose completion rates declined significantly (χ2, Pb0.001) from
dependent daughters 43% (1265/2924) to dependent spouses 21%
(157/740); the least adherent groupwas active dutywomenwith a 16%
(233/1424) completion rate. The majority of patients at the time of
vaccine initiation originated from the Primary Care (46%), and
Pediatrics/Adolescent Clinics (24%). The adherence rates by clinic
specialty in descending order were as follows: Pediatrics/Adolescent
45% (541/1205), Primary Care 38% (889/2317), Immunization 21%
(153/732), and Obstetrics/Gynecology 9% (73/834), (χ2, Pb0.001).
Among the 3 demographic categories, the groups that demonstrated the
highest 2ndand3rddose adherence rates (χ2, Pb0.001)were age group
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8–17, dependent daughters, and Pediatrics/Adolescent Clinic
population.
Timeliness of vaccination by female ITT subjects was also
determined. The median days from the initial dose to receiving
dose-2 was 76 (interquartile range, 62–136) and for dose-3 197
(interquartile range, 182–245). For dose-2 recipients 1159/2879
(40%) received delayed inoculation (3 months past vaccine initia-
tion); whereas, 450/1656 (27%) dose-3 recipients delayed the
inoculation past the 8 month mark.
For the male population, the details of the demographic data and
vaccine adherence rates by dose number are presented in Table 2. Of
the male ITT subjects (n=31), most were active duty 26/31 (84%),
vaccinated through immunization clinics 26/31 (84%), and poorly
adherent 1/31 (3%). Due to the small sample size and poor adherence
among all demographic categories, interpretation of the data is limited
and ineffectual. However, it is notable that certain demographic
groups exhibitedhigher adherence rates thanothers, i.e. age group12–
17, dependent sons, and Pediatrics/Adolescent Clinic population.
Discussion
Our study was conducted at a large naval medical center in Southern
California. The institution is comprisedofmulti-specialty clinics onsite and
numerous outlying clinics. The results of our study revealed a high rate of
usage of qHPV among various clinics since July 2006. Disappointingly, the
overall 3-dose adherence rate among females who initiated the vaccine
was relatively low (32%). The highest adherence rates (~45%) were
achieved in the female population within the adolescent, dependent
Table 1




n (%)a Yes No Odds OR (95% CI)b Yes No Odds OR (95% CI)b
n n n n
Vaccination status
Total 6792 (100)
Intent-to-vaccinate 5088 (75) 2879 2209 1.30 – 1656 3432 0.48 –
In-progress 1704 (25) 646 1058 0.61 – – – – –
Age groupc (years)
08–17d 2146 (42) 1526 620 2.46 Referentd 959 1187 0.81 Referentd
18–26 2794 (55) 1315 1479 0.89 0.36 (0.32–0.41)e 676 2118 0.32 0.40 (0.35–0.45)e
27–50 148 (3) 38 110 0.35 0.14 (0.09–0.21)e 20 128 0.16 0.19 (0.11–0.31)e
Beneficiary statusc
Dependent daughterd 2924 (57) 2024 900 2.25 Referentd 1265 1659 0.76 Referentd
Dependent spouse 740 (15) 313 427 0.73 0.33 (0.28–0.39)e 157 583 0.27 0.35 (0.29–0.42)e
Active duty 1424 (28) 542 882 0.61 0.27 (0.24–0.31)e 233 1191 0.20 0.26 (0.22–0.30)e
Clinic specialtyc
Peds/Adolescentd 1205 (24) 856 349 2.45 Referentd 541 664 0.81 Referentd
Primary Care 2317 (46) 1476 841 1.76 0.72 (0.61–0.83)e 889 1428 0.62 0.76 (0.66–0.88)e
Immunization 732 (14) 333 399 0.83 0.34 (0.28–0.41)e 153 579 0.26 0.32(0.26–0.40)e
Obstet/Gynecol 834 (16) 216 618 0.35 0.14 (0.12–0.17)e 73 761 0.10 0.12 (0.09–0.15)e
Note. Dose-1, -2, -3 = 1st, 2nd or 3rd dose of qHPV vaccine received by individual subjects within the 1-year timeframe since initiation. Yes or No indicates receipt or non-receipt of
the specified dose.
a Percentage of subjects in each demographic category.
b OR and 95% CI for the proportional difference in specified dose received between the referent and other groups within the same category.
c The total number (n=5088) in the demographic categories was derived from the intention-to-treat (ITT) population.
d Referent group for calculation of odds ratio. It is the group with the highest odds of receiving the specified dose in the demographic category.
e Pb0.001, by χ2 test.
Fig. 1. Female intention-to-treat population stratified by qHPV adherence and non-adherence. Non-adherence or adherence to the 3-dose regimen was based on 1–2 or 3 doses
received, respectively. Adherence declined significantly with increasing age.
274 J. Shen-Gunther et al. / Gynecologic Oncology 123 (2011) 272–277
children, and Pediatrics/Adolescent Clinic categories. In contrast, the
lowest adherence rates (b16%) were noted in the adult, active duty
women and those attending the Obstetrics and Gynecology clinic.
In regards to timeliness of vaccination, the majority of motivated
subjectswho received the2nd and/or 3rddoses achieved thiswithin the
confines of the recommended schedule. Counterintuitive to expecta-
tions, a greater proportion of the 2nd versus 3rd dose was received as
delayed inoculation. In general, a lapsed vaccination schedule does not
reduce final antibody levels; instead protection may be stalled until
completion of all doses [23]. In other words, a lengthy delay of the 3rd
dose may temporize instead of annul the desired immune response.
Zimmerman et al. demonstrated that an alternative qHPV schedule at 0,
2, and 12 months to be non-inferior to the standard schedule by
comparing anti-HPV type-specific titers [24]. However, clinical out-
comes were not ascertained. Consequently, the efficacy of the
alternative regimen, likewise a “delayed regimen” remains unknown.
Our data on boys andmen were limited by small numbers and wide
confidence intervals around point estimates. Hence it is difficult to
deduce anymeaningful generalizations. However, two observations are
noteworthy of comment. First, only 1/31 (3%) ITT subjects finished the
3-dose regimen. The rationale behind the overall poor adherence was
not a subject of this study but is highly concerning for future vaccine
effectiveness in the male population-at-large. Second, the majority of
males 26/31 (84%) received their vaccine directly through immuniza-
tion clinics. The propensity for these clinics is not explicitly known.
Nonetheless, it is our conjecture that acquiring the vaccine without the
need to visit a physician offers a safe sense of anonymity and privacy, as
well as, avoidance of questions regarding sexual orientation.
Due to the relative newnessof theGardasil™ vaccine, there is limited
published literature on post-marketing usage patterns and adherence
rates among various populations. Three academic centers have reported
similar low overall adherence rates in 9–26 year-old females, i.e. the
University of Cincinnati (28%), University of Maryland (29%), and
University of Michigan (19–26 year-olds) (10%) [17–19]. Higher
adherence rates (43%) were demonstrated in 9–26 year-olds belonging
to a California managed care organization and residents of North
Carolina (55%) [25,26] . The highest (64%)was among 12 year-olds in La
Spezia, Italy after an HPV vaccination campaign [27]. A possible
explanation for the greater adherence rates among pre-adolescents as
replicated in our study is the extent of parental education and depth of
child-parent involvement. The limited national statistics identified in
the literature were found in the CDC's National Immunization Survey-
Teen as cited in the Introduction [15,16]. As for global statistics, HPV
vaccine adherence rates are unknown. In the “WHO vaccine-prevent-
able diseases: 2010 global summary” issued by the World Health
Organization which contains statistical data of immunization programs
from 193 countries, HPV vaccination has been incorporated in the
immunization schedules of 29Member States as of 2009 [28]. Howbeit,
immunization coverage levels calculated as a percentage of target
population vaccinated and the number of doses completed has not been
reported for HPV vaccination. This is in contradistinction to HepB3 (3rd
dose hepatitis B vaccine) and Hib3 (3rd dose Haemophilius influenza
type b vaccine) which are examples of tracked immunizations byWHO
[29]. Furthermore, if we measured our findings against the U.S.
Department of Health and Human Services Healthy People 2010
[15,29] benchmark set at 90% vaccine coverage of all immunizations
and 90% coverage of ≥3 doses HepB (another multi-dose vaccine), our
qHPV 3-dose adherence rate would be significantly under target.
In health services research, outcomes of evaluation are often defined
in terms of efficacy, effectiveness, or efficiency. The termeffectiveness is
a measure of outcome in a “real-world” situation or post-marketing
setting where the ideal, controlled conditions of a clinical trial are
removed. The results gleaned from this study revealed the effectiveness
or lack thereof of a vaccine program. Specifically, we discovered low
overall adherence (32%) by using the 3-dose completion rate as the
index of effectiveness (Supplementary Fig. S2). If a vaccine program is
used ineffectively, its efficacy is compromised and its efficiency (benefit-
cost ratio) diminished. The eventual impact would be twofold, that is, a
detriment to population health and health expenditure.
The strength of this study lies in the large sample studied which is
capable of generating population statistics and trends. This was made
possible with the use of AHLTA which is a repository of outpatient
medical records of all U.S. military beneficiaries (~9.4 million) [30].
This study captured almost 7000 military beneficiaries from the San
Table 2




n (%)a Yes No Odds OR (95% CI)b Yes No Odds OR (95% CI)b
n n n n
Vaccination status
Total 46 (100)
Intent-to-vaccinate 31 (67) 2 29 0.07 – 1 30 0.03 –
In-progress 15 (33) 3 12 0.25 – – – – –
Age groupc (years)
12–17d 5 (16) 1 4 0.25 Referentd 1 4 0.25 Referentd
18–26 16 (52) 0 16 0 0 0 16 0 0
27–51 10 (32) 1 9 0.11 0.44 (0.005–43.5)e 0 10 0 0
Beneficiary statusc
Dependent sond 5 (16) 1 4 0.25 Referentd 1 4 0.25 Referentd
Active duty 26 (84) 1 25 0.04 0.16 (0.002–15.7)e 0 25 0 0
Clinic specialtyc
Peds/Adolescentd 2 (6) 1 1 0.50 Referentd 1 1 0.50 Referentd
Primary Care 3 (10) 0 3 0 0 0 3 0 0
Immunization 26 (84) 1 25 0.04 0.04 (0.0005–6.3)e 0 26 0 0
Note. Dose-1, -2, -3 = 1st, 2nd or 3rd dose of qHPV vaccine received by individual subjects within the 1-year timeframe since initiation. Yes or No indicates receipt or non-receipt of
the specified dose.
a Percentage of subjects in each demographic category.
b OR and 95% CI for the proportional difference in specified dose received between the referent and other groups within the same category.
c The total number (n=31) in the demographic categories was derived from the intention-to-treat (ITT) population.
d Referent group for calculation of odds ratio. It is the group with the highest odds of receiving the specified dose in the demographic category.
e PN0.05, by exact test.
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Diego metropolitan area who visited numerous clinics at various
locations. Since AHLTA is the common digital repository, those who
received their inoculations at different sites on different dates were
captured and recorded. It is possible that some patients may have
received or completed the vaccine series in the civilian sector
resulting in loss of data. Examples of civilian sources of qHPV
vaccination include private-practice physicians, university hospitals
or clinics, and county health clinics. We believe this subset is small
due to the difference in out-of-pocket expense, i.e. $125/dose in
civilian versus $0 in the Military Healthcare System (MHS). The
monetary incentive leans toward staying within the MHSwhich lends
supports to the completeness of our data and validity of results.
Cross-sectional studies, like other types of observational research,
are susceptible to errors due to chance or bias.We acknowledge that the
current study has limitations. First, the potential for selection bias must
be considered. The study population was derived from a large naval
medical center in Southern California. Our results may not be
representative of other branches of the military or the civilian
population. To investigate this, a similar study is planned to survey
the Army and Air Force beneficiaries of San Antonio Military Medical
Center (SAMMC) in San Antonio, Texas. Second, this study is limited in
terms of understanding the rationale behind non-adherence. The
underlying cognitive, psychosocial, behavioral, and/or circumstantial
reasons, as identified in adherence research, were not assessed due to
the nature of the design and the use of electronicmedical records as the
data source. Previous studies have also examined socioeconomic
reasons and insurance status as predictors of poor adherence
[17–19,25]. These particular concerns may not be applicable to the
military population since health care insurance is essentially universal.
Instead, military unique circumstancesmust be explored to understand
the disincentives for vaccine completion. We surmise that inconve-
nience, time-constraints, side effects (pain at injection site), relocation,
and deployments all have an impact on vaccine non-adherence. In
particular, U.S. deployment statistics are staggering with current and
unforeseen long-term social, emotional, and behavioral effects on the
servicemember, their children and families [31]. Since September 2001,
over 2 million U.S. service members have deployed to Afghanistan or
Iraq and 800,000 have deployed at least twice [31]. Decidedly, further
investigation is urgently needed to answer the question “what causes
non-adherence” in effort to design meaningful interventions.
In conclusion, this study has provided insight into the real-world
suboptimal use of Gardasil™ HPV vaccine. Establishing an HPV vaccine
registry andmonitoring program at ourmedical centers and clinicsmay
improve adherence rates which is paramount to achieving optimal
benefit from the quadrivalent vaccine. At the current state, the true
efficacy of HPV vaccination among the populace remains uncertain.
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